At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 104 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Terazosine 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase One of Study on Urinary Stent Complications and Treatment
In Brief
A Phase 3 clinical trial evaluating Placebo, Terazosine, and 2 other interventions for Disorder of Urinary Stent. Completed, enrolled 104 participants across 1 site.
Detailed Summary
The aim of the investigators study is to evaluate whether alpha-blockers such as terazosin and anti-cholinergics such as tolterodine can be relieve the DJ-stent related symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisorder of Urinary Stent
CountriesIran
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedFeb 2012
Primary CompletionAug 2012
Study CompletionSep 2012
TodayJul 2026
First PostedFeb 9, 2012
Enrollment StartJan 1, 2012
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.4 years ago
Interventions
Placebodrug
same as tolterodine and terazosin dose
Terazosinedrug
2 mg BID
Tolterodinedrug
2 mg daily
Tolterodine + Terazosindrug
2mg daily and 2mg BID